• Profile
Close

Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

The Prostate Aug 08, 2019

Wang J, Xu W, Mierxiati A, et al. - A total of 449 individuals with neuroendocrine prostate cancer (NEPC), including 352 cases of pure NEPC and 97 cases of neuroendocrine (NE) differentiation, together with 408,629 cases of prostate adenocarcinoma at diagnosis were reclaimed from the Surveillance, Epidemiology, and End Results program (2010-2015) by the researchers in order to elucidate the clinical features of the primary NEPC and primary adenocarcinoma with NE differentiation. In comparison with NE differentiation and prostate adenocarcinoma, pure NEPC had greater rates of visceral metastases but a lower rate of bone metastasis. Furthermore, individuals diagnosed with pure NEPC vs individuals with NE differentiation and prostate adenocarcinoma had a poorer outcome. The adjusted HRs for prostate-specific antigen (PSA) lower than or equal to 4.0 ng/mL were 2.24 and 1.57 in the NE differentiation group and in the pure NEPC group, respectively, using PSA 4.1 to 10 ng/mL as the reference. Hence, individuals with NE differentiation had various clinical features and a better prognosis as that of individuals with pure NEPC. Moreover, in individuals with either NEPC or NE differentiation, low-serum PSA levels were correlated with a poorer prognosis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay